Navigation Links
Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
Date:1/6/2011

THE WOODLANDS, Texas, Jan. 6, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

Results from the study demonstrated that administration of a 300 mg solid oral tablet dose of LX4211, administered as two 150 mg tablets, significantly increased total GLP-1 (p=0.001), active GLP-1 (p=0.032) and PYY (p=0.004), important mediators of glycemic and appetite control as well as other metabolic parameters.  Notably, single doses of LX4211 produced rapid and significant improvement in post-prandial glucose (PPG) and fasting plasma glucose (FPG), consistent with results seen in the previous Phase 2 study. Pharmacokinetic and pharmacodynamic data from the study indicated that the solid oral formulation worked as well as or better than the liquid formulation on key parameters of hormonal release, PPG and FPG.  Lexicon plans to move the tablet formulation forward into a Phase 2b study in the second quarter of 2011.

"The significant elevations of GLP-1 levels observed in the study are particularly important given its established relevance in the treatment of diabetes," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer.  "Newly observed in this study was the effect of LX4211 on increasing circulating levels of PYY.  We believe the rapid reduction in blood sugar levels after meals, the increase in GLP-1 and the increase in PYY are all associated with SGLT1 inhibition by LX4211 in the gastrointestinal tract."

PYY and GLP-1 are g
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
2. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
4. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
5. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
6. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
9. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
10. Lexicon to Present at BIO International Convention
11. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Final shortlist announced, winners ... The second edition of the much-awaited VCCircle Healthcare Awards is ... the final nominations for the 2014 honours.  The names ... of September 25 at The Taj Mahal Palace, Mumbai ... a variety of qualitative and quantitative parameters - such ...
(Date:9/22/2014)... Research and Markets has announced the addition ... report to their offering. Worldwide ... despite the presence of many cholesterol-lowering drugs in the ... been ubiquitously prescribed over the last 25 years. Researchers ... is the cornerstone of assessing heart risk. Irrespective of ...
(Date:9/22/2014)... , Sept. 22, 2014  Continua and ... in healthcare technology, media and telecommunications,  have formed ... China and promote international ... BHG announced this new partnership during the global ... Washington, DC , while also ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4
... Medical Imaging today announced that the company has been ... Office covering technology for its COR Analyzer® System.  The ... Angiography (cCTA) studies to accelerate emergency department triage of ... and radiology department workflow. The System is marketed in ...
...   Shire plc (LSE: SHP, NASDAQ: ... that following the,satisfaction of the closing conditions, including the ... of 1976, the acquisition of Advanced BioHealing, Inc. ("ABH"),as ... The Advanced BioHealing business becomes part of ...
Cached Medicine Technology:Rcadia Medical Imaging Awarded Four U.S. Patents Covering Technology for Automated Analysis of Coronary CT Angiography 2Shire Completes Acquisition of Advanced BioHealing, Inc. 2
(Date:9/22/2014)... patients undergoing breast cancer surgery require additional operations because ... in the initial operation. However, researchers at Brigham and ... developed that will help surgeons better distinguish cancerous breast ... repeat operations. , The study is ... the Proceedings of the National Academy of Sciences ...
(Date:9/22/2014)... PITTSBURGH, PA (PRWEB) September 22, 2014 ... caring for patients to the problem of side-sleeping. "My ... my side, so I designed a solution to this ... fall asleep comfortably than to have your arm 'fall ... sleep on his or her side more comfortably. It ...
(Date:9/22/2014)... London, UK (PRWEB) September 22, 2014 ... growth in the recent years. The statistically important data ... and safety of cancer vaccines. The primary challenge to ... sufficient information about the exact mechanism of how a ... leads to various results in different individuals owing to ...
(Date:9/22/2014)... Barbara Bronson Gray HealthDay Reporter ... every pregnant woman wonders: What can I do to help ... iron supplements as prescribed may play a role in reducing ... (ASD). The researchers found that mothers of children with ... before and during pregnancy than those whose children seem to ...
(Date:9/22/2014)... Diego CA (PRWEB) September 22, 2014 ... significantly expand its work to equip women around the ... on poverty. Through the Women Empowered (WE) Initiative ... will now join community-led groups to pool their savings, ... , “Women are the solution to ending poverty in ...
Breaking Medicine News(10 mins):Health News:The fine line between breast cancer and normal tissues 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3
... has warned about the inherent risks involved in the ... ,The human milk is capable of causing food ... chances that the human milk carries remnants of drugs ... unhygienic storage of milk, and not adhering to hygienic ...
... health care workers in the United States has risen, ... settings.// ,According to Vanderbilt infectious disease experts ... treatment should be provided to health care workers with ... skin test, particularly if they meet certain high-risk criteria. ...
... company Venus Remedies Ltd today said it has ... latest antibiotic fixed dose combination used in the ... new antibiotic combination, active against multi-resistant strains of ... a broad-spectrum coverage of bactericidal activity, it informed ...
... to seek help from a doctor or mental health professional, ... it difficult to obtain adequate// treatment or medication, according to ... to treatment for people with suicide ideation," said Ruth Klap, ... and study co-author. "There is a problem with perceived need ...
... orphans and vulnerable children (OVC) need to be prioritized in ... report, 'A Call to Action: Children, the Missing Face of ... of children and also to realize the targets chartered in ... maternal health, for the year 2015. ,Anti –AIDs ...
... by most Britons are packed with dust mites, fungus and skin ... was found to contain up to 20,000 live house dust mites ... an 11-year unwashed duvet revealed over an ounce and a half ... ,In addition it was found that more than four in ...
Cached Medicine News:Health News:Many Suicidal Adults Aren't Getting Mental Health Treatment 2Health News:Dust mites use Duvets as their Haven 2
... innovative stent allows the physician to intubate the ... with just topical anesthetic drops., ,The SRS is ... in three lengths 25mm, 30mm and 35mm (disposable ... stent is an anchor-shaped head to provide fixation. ...
... or somatomedin-C, is a peptide highly dependent ... promoting activity. IGF-I is transported in serum ... of growth disorders, measurements of IGF-I are ... hormone secretion. A normal plasma or serum ...
... is a high-throughput immunoassay system built around ... 2000 with the important addition of Logic ... to be designed for optimal performance with ... for critical assays such as the cardiac ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
Medicine Products: